HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
News
Current market catalysts
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
Latest Headlines
30 headlines
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.
UBS Maintains Sell on JetBlue Airways, Lowers Price Target to $4
UBS analyst Atul Maheswari maintains JetBlue Airways (NASDAQ:JBLU) with a Sell and lowers the price target from $5 to $4.
TotalEnergies Finds More Oil In Angola
TotalEnergies discovers oil at Angola's Acacia-5 block with fast-track production plans. TTE stock outperforms as exploration expands.
Oil Prices Could Be Headed Even Higher as US Emergency Reserve Falls to 1980s Low — Market Strategist Says $200 Oil Risk Is Growing
Detrick warns oil prices could surge as the U.S. SPR falls to its lowest level since the early 1980s amid the Iran conflict.
Full Transcript: Shoe Station Group Q2 2026 Earnings Call
Shoe Station Group (NASDAQ:SHOE) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
UBS Maintains Buy on Delta Air Lines, Lowers Price Target to $99
UBS analyst Atul Maheswari maintains Delta Air Lines (NYSE:DAL) with a Buy and lowers the price target from $112 to $99.
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from its Phase 2 reACHin trial.
UBS Maintains Neutral on Cooper Companies, Lowers Price Target to $66
UBS analyst Patrick Wood maintains Cooper Companies (NASDAQ:COO) with a Neutral and lowers the price target from $75 to $66.
Tenon Medical Stock Surges Thursday: What's Driving the Action?
Tenon Medical is surging Thursday after it announced the early repayment of its senior convertible notes, eliminating a dilutive overhang.
Full Transcript: Lesaka Technologies Q4 2026 Earnings Call
On Thursday, Lesaka Technologies (NASDAQ:LSAK) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
CoreWeave Rolls Out Physical AI Field Engineering
CoreWeave, Inc. (NASDAQ:CRWV), The Essential Cloud for AI™, today announced the launch of Physical AI Field Engineering, an offering that pairs customer teams with domain specialists to build, validate, and deploy AI
UBS Maintains Neutral on Casey's General Stores, Lowers Price Target to $720
UBS analyst Mark Carden maintains Casey's General Stores (NASDAQ:CASY) with a Neutral and lowers the price target from $925 to $720.
8-K filing — T3 Defense Inc. (DFNSW)
Filed: 2026-09-10 AccNo: 0001185185-26-003911 Size: 503 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Designer Brands Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Designer Brands (NYSE:DBI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
UBS Maintains Neutral on Baker Hughes, Lowers Price Target to $70
UBS analyst Josh Silverstein maintains Baker Hughes (NASDAQ:BKR) with a Neutral and lowers the price target from $71 to $70.
UBS Maintains Buy on Alaska Air Group, Lowers Price Target to $52
UBS analyst Atul Maheswari maintains Alaska Air Group (NYSE:ALK) with a Buy and lowers the price target from $56 to $52.
Nasdaq Down Over 200 Points; US Producer Inflation Rises to 5.4% In August
U.S. stocks fell as August producer prices rose 5.4% year-over-year. Oil jumped 4%, while Asian and European markets were mixed to lower.
Lovesac Reports Q2 2027 Results: Full Earnings Call Transcript
Lovesac (NASDAQ:LOVE) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320
HSBC analyst Rajesh Kumar maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $290 to $320.
'Walmart Expands Restaurant Delivery With Papa John’s Deal' - Bloomberg
https://www.bloomberg.com/news/articles/2026-09-10/walmart-expands-restaurant-delivery-with-papa-john-s-deal
Transcript: Haivision Systems Q3 2026 Earnings Conference Call
Haivision Systems (TSX:HAI) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
What's Happening With Ocugen Stock Thursday?
Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing interim clinical trial data.
UBS Maintains Buy on American Eagle Outfitters, Lowers Price Target to $27
UBS analyst Jay Sole maintains American Eagle Outfitters (NYSE:AEO) with a Buy and lowers the price target from $31 to $27.
Hot PPI Sinks Gold, Freight Stocks: 10 Names To Watch Thursday
August PPI ran hot at 5.4%. Gold fell 2%, the 10-year hit 4.90% and economists split on a September Fed hike.
HSBC Maintains Buy on Merck & Co, Raises Price Target to $172
HSBC analyst Rajesh Kumar maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $150 to $172.
HSBC Maintains Hold on Pfizer, Raises Price Target to $30
HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.
UBS Maintains Buy on American Airlines Group, Lowers Price Target to $17
UBS analyst Atul Maheswari maintains American Airlines Group (NASDAQ:AAL) with a Buy and lowers the price target from $18 to $17.
Goldman Sachs Increases COIN Target to $219 on 'Everything Exchange' Push
Goldman Sachs reaffirmed Coinbase’s Buy rating and raised its target to $219, citing growth in derivatives, prediction markets, tokenized equities, margin lending, Base and agentic finance.
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.
- Source
- Source-attributed market-news archive
- Observed
- Checked
- Cadence
- Continuous captured-news feed
- Status
- fresh